Literature DB >> 31253577

Hepatocellular carcinoma: Current situation and challenge.

Zhao Li1, Ji-Ye Zhu2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31253577     DOI: 10.1016/j.hbpd.2019.05.013

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


× No keyword cloud information.
  6 in total

1.  All-trans-retinoic acid inhibits the malignant behaviors of hepatocarcinoma cells by regulating autophagy.

Authors:  Shuyu Fang; Chaoqun Hu; Lei Xu; Jiejie Cui; Li Tao; Mengjia Gong; Yi Wang; Yun He; Tongchuan He; Yang Bi
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 2.  Exosomes as therapeutic vehicles in liver diseases.

Authors:  Jingyi Ding; Ju Wang; Jiajia Chen
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.

Authors:  Yichao Wu; Zhikun Liu; Xiao Xu
Journal:  Cancer Commun (Lond)       Date:  2020-12-08

4.  Self-Activated Cascade-Responsive Sorafenib and USP22 shRNA Co-Delivery System for Synergetic Hepatocellular Carcinoma Therapy.

Authors:  Shengjun Xu; Sunbin Ling; Qiaonan Shan; Qianwei Ye; Qifan Zhan; Guangjiang Jiang; Jianyong Zhuo; Binhua Pan; Xue Wen; Tingting Feng; Haohao Lu; Xuyong Wei; Haiyang Xie; Shusen Zheng; Jiajia Xiang; Youqing Shen; Xiao Xu
Journal:  Adv Sci (Weinh)       Date:  2021-01-15       Impact factor: 16.806

5.  Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts.

Authors:  Jianyong Zhuo; Di Lu; Jianguo Wang; Zhengxing Lian; Jiali Zhang; Huihui Li; Beini Cen; Xuyong Wei; Qiang Wei; Haiyang Xie; Xiao Xu
Journal:  Chin J Cancer Res       Date:  2021-08-31       Impact factor: 5.087

6.  Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells: A protocol of systematic review and meta-analysis.

Authors:  Jing Li; Zhi-Ye Liu; Hai-Bo Yu; Qing Xue; Xiu-Sheng Qu
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.